Crossmark

Faricimab for treatment-resistant choroidal neovascularization (CNV) in neovascular age-related macular degeneration (nAMD): seven-months results using artificial intelligence and OCTA

Crossref DOI link: https://doi.org/10.1186/s40942-025-00691-4

Published Online: 2025-06-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Heinke, Anna

Warter, Alexandra

Nagel, Ines D.

Agnihotri, Akshay

Mehta, Nehal Nailesh

Galang, Carlo Miguel B.

Deussen, Daniel N.

Bartsch, Dirk-Uwe G.

Cheng, Lingyun

Ferreyra, Henry A.

Freeman, William R.
Funding

Funding for this research was provided by:

NIH (OT2OD032644)

NIH (R01EY016323)

NIH (R01EY033847)
License Information

Text and Data Mining valid from 2025-06-17

Version of Record valid from 2025-06-17
More Information

Article History

Received: 6 February 2025

Accepted: 5 June 2025

First Online: 17 June 2025

Declarations

:

: UCSD Institutional Review Board (IRB Nr#120516) approval was acquired for the review and analysis of patient data. All procedures adhered to the tenets of the Declaration of Helsinki for research involving human subjects and complied with Health Insurance Portability and Accountability Act (HIPAA) regulations.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below